Aethlon Medical Stock Price, News & Analysis

Aethlon Medical (NASDAQ: AEMD) has achieved a significant milestone by treating the first patient with its Hemopurifier device in an Australian clinical trial. The trial focuses on patients with solid tumors who show stable or progressive disease during anti-PD-1 monotherapy treatments like Keytruda® or Opdivo®.

The first patient, who showed disease progression after two months of Nivolumab treatment, received a 4-hour Hemopurifier treatment on January 29, 2025, at the Royal Adelaide Hospital, tolerating the procedure without complications. The trial aims to enroll approximately 18 patients to assess safety, feasibility, and optimal dosing.

The Hemopurifier is designed to remove tumor-derived extracellular vesicles (EVs) from the bloodstream, potentially improving response rates to anti-PD-1 therapies, which currently only benefit 30-40% of patients. The study will evaluate different treatment intervals and analyze changes in EV concentrations to inform future Premarket Approval studies.

Aethlon Medical (NASDAQ: AEMD) has provided an update on its investigational Hemopurifier device's capability to capture H5N1 Bird Flu virus. The update comes amid rising concerns over Bird Flu cases in dairy cows and humans across eight states, including a severe case in Louisiana and California's state of emergency declaration.

Laboratory tests at Battelle labs demonstrated that a miniature version of the Hemopurifier removed 99% of H5N1 after 6 hours of treatment in vitro. The device, which removes enveloped viruses from bloodstream, has been used in 38 patients across 164 treatment sessions for various diseases including hepatitis C, HIV, COVID-19, and Ebola. The Hemopurifier holds FDA 'breakthrough device' designation for life-threatening viruses lacking effective treatments.

Aethlon Medical (NASDAQ: AEMD) reported key developments in its fiscal Q2 2024, including the enrollment of two patients in its Australian clinical trial for the Hemopurifier® device. The trial focuses on treating solid tumor patients who haven't responded to anti-PD-1 therapies. The company has expanded its trial sites, with Pindara Private Hospital now approved for enrollment and a third Australian hospital in the approval process. Additionally, Medanta Medicity Hospital in India received ethics committee approval for a similar trial. The company has implemented cost-cutting measures while maintaining focus on its oncology trials. This comes amid projections showing the solid tumors market is expected to reach $375.4 Billion by 2034.

Aethlon Medical (AEMD) reported fiscal Q2 2024 results and key developments. The company achieved enrollment of first two patients in its Hemopurifier® cancer trial at Royal Adelaide Hospital, Australia. A second site, Pindara Private Hospital, is now open for enrollment. The company received ethics committee approval from Medanta Medicity Hospital in India for a similar trial. Financial highlights include cash balance of $6.9 million and reduced operating expenses to $2.9 million, down 9% year-over-year. Net loss decreased to $2.8 million from $3.0 million in the prior year period. The company implemented cost-cutting measures and appointed James Frakes as permanent CEO.

Aethlon Medical (NASDAQ: AEMD) announced enrollment of its first patient in an Australian clinical trial for the Hemopurifier®, a device designed to combat cancer and viral infections. The trial focuses on patients with solid tumors showing stable or progressive disease during anti-PD-1 therapy. The first patient, enrolled on October 29, 2024, at Royal Adelaide Hospital, will undergo a two-month run-in period receiving anti-PD-1 therapy before potential Hemopurifier treatment. The trial aims to improve upon current 30-40% response rates to anti-PD-1 therapies by removing tumor-produced EVs from the bloodstream. The study will involve 9-18 patients and evaluate safety, feasibility, and optimal treatment intervals.

Aethlon Medical (AEMD) has enrolled the first patient in its Australian clinical trial of the Hemopurifier® at Royal Adelaide Hospital. The trial aims to evaluate safety, feasibility, and dosing in patients with solid tumors who haven't responded to anti-PD-1 therapies like Keytruda® or Opdivo®. The enrolled patient began a two-month run-in period on October 29, 2024, receiving anti-PD-1 therapy.

The trial will include 9-18 patients, focusing on the Hemopurifier's ability to remove tumor-produced Extracellular vesicles (EVs) from bloodstream. Currently, only about 30% of patients respond to anti-PD-1 therapies, and the company hopes to improve these response rates through their treatment.

Aethlon Medical (Nasdaq: AEMD), a medical therapeutic company developing products for cancer and infectious diseases treatment, announced it will release its fiscal second quarter financial results for the period ended September 30, 2024, on November 13, 2024 at 4:15 p.m. ET. The company will host a conference call at 4:30 p.m. ET the same day, featuring management's remarks and a Q&A session. Participants can register online or dial in directly, with replay available until December 13, 2024.

Aethlon Medical (Nasdaq: AEMD), a company developing products for cancer and infectious disease treatment, announced its participation in the 2024 Maxim Healthcare Virtual Summit. James Frakes, CEO and CFO, will engage in a fireside chat on October 15, 2024, at 4:30 pm ET.

The event, hosted by Anthony Vendetti, executive managing director and head of research at Maxim Group, offers an opportunity for investors to gain insights into Aethlon Medical's developments and strategies. Interested parties can access the company presentation by registering for the conference through the provided link.

Investorideas.com releases the second part of a series on immunotherapy for cancer treatment, featuring Aethlon Medical, Inc. (NASDAQ: AEMD). Key points include:

1. Immunotherapy shows promise in improving long-term survival for advanced melanoma patients.

2. Aethlon's Hemopurifier® aims to enhance anti-PD-1 therapy responses by removing tumor-produced extracellular vesicles.

3. Aethlon received ethics approval for a clinical trial in India, following approvals in Australia.

4. The trial will evaluate Hemopurifier® in solid tumor patients with stable or progressive disease during anti-PD-1 monotherapy.

5. Other companies like Immuneering and Iovance Biotherapeutics are also advancing immunotherapy treatments with promising results.